Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD

Brain Research Bulletin

Volumn 72, Issue 2-3 SPEC. ISS., 2007, Pages 108-120

  Glynn, Dervila ^a   Reim, Kerstin ^b   Brose, Nils ^b   Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Behaviour; Complexin; Crossbreeding experiment; Huntington's disease; Synaptic transmission

Indexed keywords

COMPLEXIN II; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUNTINGTON DISEASE; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 33847680185     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2006.10.017     Document Type: Article

References (45)

1. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., and Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4 (2004) 3943-3952
2. Bates G., Harper P.S., and Jones L. Huntington's Disease. 3rd ed. (2002), Oxford University Press, Oxford
3. Butterworth M.B., Frizzell R.A., Johnson J.P., Peters K.W., and Edinger R.S. PKA-dependent ENaC trafficking requires the SNARE-binding protein complexin. Am. J. Physiol. Renal Physiol. 289 (2005) F969-F977
4. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterisation of progressive motor deficits in mice transgenic for the Huntington's disease mutation. J. Neurosci. 19 (1999) 3248-3257
5. Carter R.J., Hunt M.J., and Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Movement Disord. 15 (2000) 925-937
6. Chai Y., Koppenhafer S.L., Bonini N.M., and Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 19 (1999) 10338-10347
7. Chen Y.A., and Scheller R.H. SNARE-mediated membrane fusion. Nat. Rev. Mol. Cell Biol. 2 (2001) 98-106
8. DiProspero N.A., Chen E.Y., Charles V., Plomann M., Kordower J.H., and Tagle D.A. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol. 33 (2004) 517-533
9. Eastwood S.L., Cotter D., and Harrison P.J. Cerebellar synaptic protein expression in schizophrenia. Neuroscience 105 (2001) 219-229
10. Eastwood S.L., and Harrison P.J. Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. Mol. Psychiatr. 5 (2000) 425-432
11. Eastwood S.L., and Harrison P.J. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res. Bull. 55 (2001) 569-578
12. Eastwood S.L. The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame?. Int. Rev. Neurobiol. 59 (2004) 47-72
13. Eastwood S.L., and Harrison P.J. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr. Res. 73 (2005) 159-172
14. Edwardson J.M., Wang C.T., Gong B., Wyttenbach A., Bai J., Jackson M.B., Chapman E.R., and Morton A.J. Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J. Biol. Chem. 278 (2003) 30849-30853
15. Fernandez-Funez P., Nino-Rosales M.L., de Gouyon B., She W.C., Luchak J.M., Martinez P., Turiegano E., Benito J., Capovilla M., Skinner P.J., McCall A., Canal I., Orr H.T., Zoghbi H.Y., and Botas J. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408 (2000) 101-106
16. Freeman W., and Morton A.J. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res. Bull. 63 (2004) 45-55
17. Gibson H.E., Reim K., Brose N., Morton A.J., and Jones S. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur. J. Neurosci. 22 (2005) 1701-1712
18. Glynn D., Bortnick R.A., and Morton A.J. Complexin II is essential for normal neurological function in mice. Hum. Mol. Genet. 12 (2003) 2431-2448
19. Hansson O., Nylandsted J., Castilho R.F., Leist M., Jaattela M., and Brundin P. Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Res. 970 (2003) 47-57
20. Harrison P.J., and Eastwood S.L. Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia. Lancet 352 (1998) 1669-1673
21. Hatcher J.P., Jones D.N., Rogers D.C., Hatcher P.D., Reavill C., Hagan J., and Hunter A.J. Development of SHIRPA to characterise the phenotype of gene-targeted mice. Behav. Brain Res. 125 (2001) 43-47
22. Hazell A.S., and Wang C. Downregulation of complexin I and complexin II in the medial thalamus is blocked by N-acetylcysteine in experimental Wernicke's encephalopathy. J. Neurosci. Res. 79 (2005) 200-207
23. Hickey M.A., Reynolds G.P., and Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 81 (2002) 46-59
24. Hunt M.J., and Morton A.J. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res. 166 (2005) 220-229
25. Hurlbert M.S., Zhou W., Wasmeier C., Kaddis F.G., Hutton J.C., and Freed C.R. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48 (1999) 649-651
26. Kandel E.R., Schwartz J.H., and Jessell T.M. Principals of Neural Science. 4th ed. (2000), McGraw-Hill
27. Li J.Y., Plomann M., and Brundin P. Huntington's disease: a synaptopathy?. Trends Mol. Med. 9 (2003) 414-420
28. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., and Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19 (1999) 10428-10437
29. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., and Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
30. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
31. McMahon H.J., Missler M., Li C., and Südhof T. Complexins: cytosolic proteins that regulate SNAP receptor function. Cell 83 (1995) 111-119
32. Morton A.J., and Edwardson J.M. Progressive depletion of CPLXII in a transgenic mouse model of Huntington's disease. J. Neurochem. 76 (2001) 166-172
33. Morton A.J., Faull R.L.M., and Edwardson J.M. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull. 56 (2001) 111-117
34. Nucifora Jr. F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., and Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (2001) 2423-2428
35. Obrietan K., and Hoyt K.R. CRE-mediated transcription is increased in Huntington's disease transgenic mice. J. Neurosci. 24 (2004) 791-796
36. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., and Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399 (1999) 263-267
37. 2+-dependent neurotransmitter release. Cell 104 (2001) 71-81
38. Rogers D.C., Fisher E.M., Brown S.D., Peters J., Hunter A.J., and Martin J.E. Behavioural and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome 8 (1997) 711-713
39. Rosenmund C., Rettig J., and Brose N. Molecular mechanisms of active zone function. Curr. Opin. Neurobiol. 13 (2003) 509-519
40. Sauvageau A., Hazel A., Desjardins P., Bouthillier A., Rose C., and Butterworth R.F. Decrease of complexin II gene expression and immunolabelling in human temporal lobe epilepsy. Brain Pathol. 10 (2000) C36-06 (published abstract)
41. Sawada K., Barr A.M., Nakamura M., Arima K., Young C.E., Dwork A.J., Falkai P., Phillips A.G., and Honer W.G. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch. Gen. Psychiatry 62 (2005) 263-272
42. Sawada K., Young C.E., Barr A.M., Longworth K., Takahashi S., Arango V., Mann J.J., Dwork A.J., Falkai P., Phillips A.G., and Honer W.G. Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. Mol. Psychiatr. 7 (2002) 484-492
43. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
44. Sudhof T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci. 27 (2004) 509-547
45. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539